Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.

Date publication

février 2018

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29250803

Résumé

The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity.

Mots clés

Adolescent, Adult, Antibodies, Monoclonal, Humanized, therapeutic use, Arthritis, drug therapy, Cohort Studies, Colitis, Ulcerative, complications, Crohn Disease, complications, Female, France, epidemiology, Humans, Inflammation, drug therapy, Inflammatory Bowel Diseases, complications, Middle Aged, Skin Diseases, drug therapy, Young Adult

Référence

Aliment. Pharmacol. Ther.. 2018 02;47(4):485-493